Global Oncology Biosimilars Market Growth 2020-2025
According to this study, over the next five years the Oncology Biosimilars market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Oncology Biosimilars business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Oncology Biosimilars market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Oncology Biosimilars, covering the supply chain analysis, impact assessment to the Oncology Biosimilars market size growth rate in several scenarios, and the measures to be undertaken by Oncology Biosimilars companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Celltrion
BIOCAD
Biocon
STADA Arzneimittel AG
Intas Pharmaceuticals
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd
Pfizer
Apotex
Sandoz International
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Oncology Biosimilars consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Oncology Biosimilars market by identifying its various subsegments.
Focuses on the key global Oncology Biosimilars manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Oncology Biosimilars with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Oncology Biosimilars submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oncology Biosimilars Consumption 2015-2025
2.1.2 Oncology Biosimilars Consumption CAGR by Region
2.2 Oncology Biosimilars Segment by Type
2.2.1 Monoclonal Antibody
2.2.2 Hematopoietic Agents
2.2.3 G-CSF
2.2.4 Others
2.3 Oncology Biosimilars Consumption by Type
2.3.1 Global Oncology Biosimilars Consumption Market Share by Type (2015-2020)
2.3.2 Global Oncology Biosimilars Revenue and Market Share by Type (2015-2020)
2.3.3 Global Oncology Biosimilars Sale Price by Type (2015-2020)
2.4 Oncology Biosimilars Segment by Application
2.4.1 Retail Pharmacies
2.4.2 Hospital Pharmacy
2.4.3 Online Pharmacy
2.5 Oncology Biosimilars Consumption by Application
2.5.1 Global Oncology Biosimilars Consumption Market Share by Type (2015-2020)
2.5.2 Global Oncology Biosimilars Value and Market Share by Type (2015-2020)
2.5.3 Global Oncology Biosimilars Sale Price by Type (2015-2020)
3 Global Oncology Biosimilars by Company
3.1 Global Oncology Biosimilars Sales Market Share by Company
3.1.1 Global Oncology Biosimilars Sales by Company (2018-2020)
3.1.2 Global Oncology Biosimilars Sales Market Share by Company (2018-2020)
3.2 Global Oncology Biosimilars Revenue Market Share by Company
3.2.1 Global Oncology Biosimilars Revenue by Company (2018-2020)
3.2.2 Global Oncology Biosimilars Revenue Market Share by Company (2018-2020)
3.3 Global Oncology Biosimilars Sale Price by Company
3.4 Global Oncology Biosimilars Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Oncology Biosimilars Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Oncology Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Oncology Biosimilars by Regions
4.1 Oncology Biosimilars by Regions
4.2 Americas Oncology Biosimilars Consumption Growth
4.3 APAC Oncology Biosimilars Consumption Growth
4.4 Europe Oncology Biosimilars Consumption Growth
4.5 Middle East & Africa Oncology Biosimilars Consumption Growth
5 Americas
5.1 Americas Oncology Biosimilars Consumption by Countries
5.1.1 Americas Oncology Biosimilars Consumption by Countries (2015-2020)
5.1.2 Americas Oncology Biosimilars Value by Countries (2015-2020)
5.2 Americas Oncology Biosimilars Consumption by Type
5.3 Americas Oncology Biosimilars Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Oncology Biosimilars Consumption by Regions
6.1.1 APAC Oncology Biosimilars Consumption by Regions (2015-2020)
6.1.2 APAC Oncology Biosimilars Value by Regions (2015-2020)
6.2 APAC Oncology Biosimilars Consumption by Type
6.3 APAC Oncology Biosimilars Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Oncology Biosimilars by Countries
7.1.1 Europe Oncology Biosimilars Consumption by Countries (2015-2020)
7.1.2 Europe Oncology Biosimilars Value by Countries (2015-2020)
7.2 Europe Oncology Biosimilars Consumption by Type
7.3 Europe Oncology Biosimilars Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Oncology Biosimilars by Countries
8.1.1 Middle East & Africa Oncology Biosimilars Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Oncology Biosimilars Value by Countries (2015-2020)
8.2 Middle East & Africa Oncology Biosimilars Consumption by Type
8.3 Middle East & Africa Oncology Biosimilars Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Oncology Biosimilars Distributors
10.3 Oncology Biosimilars Customer
11 Global Oncology Biosimilars Market Forecast
11.1 Global Oncology Biosimilars Consumption Forecast (2021-2025)
11.2 Global Oncology Biosimilars Forecast by Regions
11.2.1 Global Oncology Biosimilars Forecast by Regions (2021-2025)
11.2.2 Global Oncology Biosimilars Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Oncology Biosimilars Forecast by Type
11.8 Global Oncology Biosimilars Forecast by Application
12 Key Players Analysis
12.1 Celltrion
12.1.1 Company Information
12.1.2 Oncology Biosimilars Product Offered
12.1.3 Celltrion Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Celltrion Latest Developments
12.2 BIOCAD
12.2.1 Company Information
12.2.2 Oncology Biosimilars Product Offered
12.2.3 BIOCAD Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 BIOCAD Latest Developments
12.3 Biocon
12.3.1 Company Information
12.3.2 Oncology Biosimilars Product Offered
12.3.3 Biocon Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Biocon Latest Developments
12.4 STADA Arzneimittel AG
12.4.1 Company Information
12.4.2 Oncology Biosimilars Product Offered
12.4.3 STADA Arzneimittel AG Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 STADA Arzneimittel AG Latest Developments
12.5 Intas Pharmaceuticals
12.5.1 Company Information
12.5.2 Oncology Biosimilars Product Offered
12.5.3 Intas Pharmaceuticals Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Intas Pharmaceuticals Latest Developments
12.6 Dr. Reddy's Laboratories
12.6.1 Company Information
12.6.2 Oncology Biosimilars Product Offered
12.6.3 Dr. Reddy's Laboratories Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Dr. Reddy's Laboratories Latest Developments
12.7 Teva Pharmaceutical Industries Ltd
12.7.1 Company Information
12.7.2 Oncology Biosimilars Product Offered
12.7.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Teva Pharmaceutical Industries Ltd Latest Developments
12.8 Pfizer
12.8.1 Company Information
12.8.2 Oncology Biosimilars Product Offered
12.8.3 Pfizer Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Pfizer Latest Developments
12.9 Apotex
12.9.1 Company Information
12.9.2 Oncology Biosimilars Product Offered
12.9.3 Apotex Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Apotex Latest Developments
12.10 Sandoz International
12.10.1 Company Information
12.10.2 Oncology Biosimilars Product Offered
12.10.3 Sandoz International Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Sandoz International Latest Developments
13 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Oncology Biosimilars Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Monoclonal Antibody
Table 5. Major Players of Hematopoietic Agents
Table 6. Major Players of G-CSF
Table 7. Major Players of Others
Table 8. Global Consumption Sales by Type (2015-2020)
Table 9. Global Oncology Biosimilars Consumption Market Share by Type (2015-2020)
Table 10. Global Oncology Biosimilars Revenue by Type (2015-2020) ($ million)
Table 11. Global Oncology Biosimilars Value Market Share by Type (2015-2020) ($ Millions)
Table 12. Global Oncology Biosimilars Sale Price by Type (2015-2020)
Table 13. Global Consumption Sales by Application (2015-2020)
Table 14. Global Oncology Biosimilars Consumption Market Share by Application (2015-2020)
Table 15. Global Oncology Biosimilars Value by Application (2015-2020)
Table 16. Global Oncology Biosimilars Value Market Share by Application (2015-2020)
Table 17. Global Oncology Biosimilars Sale Price by Application (2015-2020)
Table 18. Global Oncology Biosimilars Sales by Company (2017-2019) (K Units)
Table 19. Global Oncology Biosimilars Sales Market Share by Company (2017-2019)
Table 20. Global Oncology Biosimilars Revenue by Company (2017-2019) ($ Millions)
Table 21. Global Oncology Biosimilars Revenue Market Share by Company (2017-2019)
Table 22. Global Oncology Biosimilars Sale Price by Company (2017-2019)
Table 23. Global Oncology Biosimilars Manufacturing Base Distribution and Sales Area by Manufacturers
Table 24. Players Oncology Biosimilars Products Offered
Table 25. Oncology Biosimilars Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 26. Global Oncology Biosimilars Consumption by Regions 2015-2020 (K Units)
Table 27. Global Oncology Biosimilars Consumption Market Share by Regions 2015-2020
Table 28. Global Oncology Biosimilars Value by Regions 2015-2020 ($ Millions)
Table 29. Global Oncology Biosimilars Value Market Share by Regions 2015-2020
Table 30. Americas Oncology Biosimilars Consumption by Countries (2015-2020) (K Units)
Table 31. Americas Oncology Biosimilars Consumption Market Share by Countries (2015-2020)
Table 32. Americas Oncology Biosimilars Value by Countries (2015-2020) ($ Millions)
Table 33. Americas Oncology Biosimilars Value Market Share by Countries (2015-2020)
Table 34. Americas Oncology Biosimilars Consumption by Type (2015-2020) (K Units)
Table 35. Americas Oncology Biosimilars Consumption Market Share by Type (2015-2020)
Table 36. Americas Oncology Biosimilars Consumption by Application (2015-2020) (K Units)
Table 37. Americas Oncology Biosimilars Consumption Market Share by Application (2015-2020)
Table 38. APAC Oncology Biosimilars Consumption by Regions (2015-2020) (K Units)
Table 39. APAC Oncology Biosimilars Consumption Market Share by Regions (2015-2020)
Table 40. APAC Oncology Biosimilars Value by Regions (2015-2020) ($ Millions)
Table 41. APAC Oncology Biosimilars Value Market Share by Regions (2015-2020)
Table 42. APAC Oncology Biosimilars Consumption by Type (2015-2020) (K Units)
Table 43. APAC Oncology Biosimilars Consumption Market Share by Type (2015-2020)
Table 44. APAC Oncology Biosimilars Consumption by Application (2015-2020) (K Units)
Table 45. APAC Oncology Biosimilars Consumption Market Share by Application (2015-2020)
Table 46. Europe Oncology Biosimilars Consumption by Countries (2015-2020) (K Units)
Table 47. Europe Oncology Biosimilars Consumption Market Share by Countries (2015-2020)
Table 48. Europe Oncology Biosimilars Value by Countries (2015-2020) ($ Millions)
Table 49. Europe Oncology Biosimilars Value Market Share by Countries (2015-2020)
Table 50. Europe Oncology Biosimilars Consumption by Type (2015-2020) (K Units)
Table 51. Europe Oncology Biosimilars Consumption Market Share by Type (2015-2020)
Table 52. Europe Oncology Biosimilars Consumption by Application (2015-2020) (K Units)
Table 53. Europe Oncology Biosimilars Consumption Market Share by Application (2015-2020)
Table 54. Middle East & Africa Oncology Biosimilars Consumption by Countries (2015-2020) (K Units)
Table 55. Middle East & Africa Oncology Biosimilars Consumption Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Oncology Biosimilars Value by Countries (2015-2020) ($ Millions)
Table 57. Middle East & Africa Oncology Biosimilars Value Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Oncology Biosimilars Consumption by Type (2015-2020) (K Units)
Table 59. Middle East & Africa Oncology Biosimilars Consumption Market Share by Type (2015-2020)
Table 60. Middle East & Africa Oncology Biosimilars Consumption by Application (2015-2020) (K Units)
Table 61. Middle East & Africa Oncology Biosimilars Consumption Market Share by Application (2015-2020)
Table 62. Oncology Biosimilars Distributors List
Table 63. Oncology Biosimilars Customer List
Table 64. Global Oncology Biosimilars Consumption Forecast by Countries (2021-2025) (K Units)
Table 65. Global Oncology Biosimilars Consumption Market Forecast by Regions
Table 66. Global Oncology Biosimilars Value Forecast by Countries (2021-2025) ($ Millions)
Table 67. Global Oncology Biosimilars Value Market Share Forecast by Regions
Table 68. Global Oncology Biosimilars Consumption Forecast by Type (2021-2025) (K Units)
Table 69. Global Oncology Biosimilars Consumption Market Share Forecast by Type (2021-2025)
Table 70. Global Oncology Biosimilars Value Forecast by Type (2021-2025) ($ Millions)
Table 71. Global Oncology Biosimilars Value Market Share Forecast by Type (2021-2025)
Table 72. Global Oncology Biosimilars Consumption Forecast by Application (2021-2025) (K Units)
Table 73. Global Oncology Biosimilars Consumption Market Share Forecast by Application (2021-2025)
Table 74. Global Oncology Biosimilars Value Forecast by Application (2021-2025) ($ Millions)
Table 75. Global Oncology Biosimilars Value Market Share Forecast by Application (2021-2025)
Table 76. Celltrion Product Offered
Table 77. Celltrion Oncology Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 78. Celltrion Main Business
Table 79. Celltrion Latest Developments
Table 80. Celltrion Basic Information, Company Total Revenue (in $ million), Oncology Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 81. BIOCAD Product Offered
Table 82. BIOCAD Oncology Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 83. BIOCAD Main Business
Table 84. BIOCAD Latest Developments
Table 85. BIOCAD Basic Information, Company Total Revenue (in $ million), Oncology Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 86. Biocon Product Offered
Table 87. Biocon Oncology Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 88. Biocon Main Business
Table 89. Biocon Latest Developments
Table 90. Biocon Basic Information, Company Total Revenue (in $ million), Oncology Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 91. STADA Arzneimittel AG Product Offered
Table 92. STADA Arzneimittel AG Oncology Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 93. STADA Arzneimittel AG Main Business
Table 94. STADA Arzneimittel AG Latest Developments
Table 95. STADA Arzneimittel AG Basic Information, Company Total Revenue (in $ million), Oncology Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 96. Intas Pharmaceuticals Product Offered
Table 97. Intas Pharmaceuticals Oncology Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 98. Intas Pharmaceuticals Main Business
Table 99. Intas Pharmaceuticals Latest Developments
Table 100. Intas Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Oncology Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 101. Dr. Reddy's Laboratories Product Offered
Table 102. Dr. Reddy's Laboratories Oncology Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 103. Dr. Reddy's Laboratories Main Business
Table 104. Dr. Reddy's Laboratories Latest Developments
Table 105. Dr. Reddy's Laboratories Basic Information, Company Total Revenue (in $ million), Oncology Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 106. Teva Pharmaceutical Industries Ltd Product Offered
Table 107. Teva Pharmaceutical Industries Ltd Basic Information, Company Total Revenue (in $ million), Oncology Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 108. Teva Pharmaceutical Industries Ltd Main Business
Table 109. Teva Pharmaceutical Industries Ltd Latest Developments
Table 110. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 111. Pfizer Product Offered
Table 112. Pfizer Oncology Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 113. Pfizer Main Business
Table 114. Pfizer Latest Developments
Table 115. Pfizer Basic Information, Company Total Revenue (in $ million), Oncology Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 116. Apotex Product Offered
Table 117. Apotex Oncology Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 118. Apotex Main Business
Table 119. Apotex Latest Developments
Table 120. Apotex Basic Information, Company Total Revenue (in $ million), Oncology Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 121. Sandoz International Product Offered
Table 122. Sandoz International Oncology Biosimilars Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 123. Sandoz International Main Business
Table 124. Sandoz International Latest Developments
Table 125. Sandoz International Basic Information, Company Total Revenue (in $ million), Oncology Biosimilars Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Oncology Biosimilars
Figure 2. Oncology Biosimilars Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Oncology Biosimilars Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Oncology Biosimilars Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Monoclonal Antibody
Figure 7. Product Picture of Hematopoietic Agents
Figure 8. Product Picture of G-CSF
Figure 9. Product Picture of Others
Figure 10. Global Oncology Biosimilars Consumption Market Share by Type (2015-2020)
Figure 11. Global Oncology Biosimilars Value Market Share by Type (2015-2020)
Figure 12. Oncology Biosimilars Consumed in Retail Pharmacies
Figure 13. Global Oncology Biosimilars Market: Retail Pharmacies (2015-2020) (K Units)
Figure 14. Global Oncology Biosimilars Market: Retail Pharmacies (2015-2020) ($ Millions)
Figure 15. Oncology Biosimilars Consumed in Hospital Pharmacy
Figure 16. Global Oncology Biosimilars Market: Hospital Pharmacy (2015-2020) (K Units)
Figure 17. Global Oncology Biosimilars Market: Hospital Pharmacy (2015-2020) ($ Millions)
Figure 18. Oncology Biosimilars Consumed in Online Pharmacy
Figure 19. Global Oncology Biosimilars Market: Online Pharmacy (2015-2020) (K Units)
Figure 20. Global Oncology Biosimilars Market: Online Pharmacy (2015-2020) ($ Millions)
Figure 21. Global Oncology Biosimilars Consumption Market Share by Application (2015-2020)
Figure 22. Global Oncology Biosimilars Value Market Share by Application (2015-2020)
Figure 23. Global Oncology Biosimilars Sales Market Share by Company in 2017
Figure 24. Global Oncology Biosimilars Sales Market Share by Company in 2019
Figure 25. Global Oncology Biosimilars Revenue Market Share by Company in 2017
Figure 26. Global Oncology Biosimilars Revenue Market Share by Company in 2019
Figure 27. Global Oncology Biosimilars Sale Price by Company in 2019
Figure 28. Global Oncology Biosimilars Consumption Market Share by Regions 2015-2020
Figure 29. Global Oncology Biosimilars Value Market Share by Regions 2015-2020
Figure 30. Americas Oncology Biosimilars Consumption 2015-2020 (K Units)
Figure 31. Americas Oncology Biosimilars Value 2015-2020 ($ Millions)
Figure 32. APAC Oncology Biosimilars Consumption 2015-2020 (K Units)
Figure 33. APAC Oncology Biosimilars Value 2015-2020 ($ Millions)
Figure 34. Europe Oncology Biosimilars Consumption 2015-2020 (K Units)
Figure 35. Europe Oncology Biosimilars Value 2015-2020 ($ Millions)
Figure 36. Middle East & Africa Oncology Biosimilars Consumption 2015-2020 (K Units)
Figure 37. Middle East & Africa Oncology Biosimilars Value 2015-2020 ($ Millions)
Figure 38. Americas Oncology Biosimilars Consumption Market Share by Countries in 2019
Figure 39. Americas Oncology Biosimilars Value Market Share by Countries in 2019
Figure 40. Americas Oncology Biosimilars Consumption Market Share by Type in 2019
Figure 41. Americas Oncology Biosimilars Consumption Market Share by Application in 2019
Figure 42. United States Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 43. United States Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 44. Canada Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 45. Canada Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 46. Mexico Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 47. Mexico Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 48. APAC Oncology Biosimilars Consumption Market Share by Countries in 2019
Figure 49. APAC Oncology Biosimilars Value Market Share by Regions in 2019
Figure 50. APAC Oncology Biosimilars Consumption Market Share by Type in 2019
Figure 51. APAC Oncology Biosimilars Consumption Market Share by Application in 2019
Figure 52. China Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 53. China Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 54. Japan Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 55. Japan Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 56. Korea Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 57. Korea Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 58. Southeast Asia Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 59. Southeast Asia Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 60. India Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 61. India Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 62. Australia Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 63. Australia Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 64. Europe Oncology Biosimilars Consumption Market Share by Countries in 2019
Figure 65. Europe Oncology Biosimilars Value Market Share by Countries in 2019
Figure 66. Europe Oncology Biosimilars Consumption Market Share by Type in 2019
Figure 67. Europe Oncology Biosimilars Consumption Market Share by Application in 2019
Figure 68. Germany Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 69. Germany Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 70. France Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 71. France Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 72. UK Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 73. UK Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 74. Italy Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 75. Italy Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 76. Russia Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 77. Russia Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 78. Middle East & Africa Oncology Biosimilars Consumption Market Share by Countries in 2019
Figure 79. Middle East & Africa Oncology Biosimilars Value Market Share by Countries in 2019
Figure 80. Middle East & Africa Oncology Biosimilars Consumption Market Share by Type in 2019
Figure 81. Middle East & Africa Oncology Biosimilars Consumption Market Share by Application in 2019
Figure 82. Egypt Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 83. Egypt Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 84. South Africa Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 85. South Africa Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 86. Israel Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 87. Israel Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 88. Turkey Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 89. Turkey Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 90. GCC Countries Oncology Biosimilars Consumption Growth 2015-2020 (K Units)
Figure 91. GCC Countries Oncology Biosimilars Value Growth 2015-2020 ($ Millions)
Figure 92. Global Oncology Biosimilars Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 93. Global Oncology Biosimilars Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 94. Americas Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 95. Americas Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 96. APAC Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 97. APAC Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 98. Europe Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 99. Europe Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 100. Middle East & Africa Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 101. Middle East & Africa Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 102. United States Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 103. United States Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 104. Canada Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 105. Canada Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 106. Mexico Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 107. Mexico Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 108. Brazil Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 109. Brazil Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 110. China Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 111. China Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 112. Japan Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 113. Japan Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 114. Korea Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 115. Korea Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 116. Southeast Asia Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 117. Southeast Asia Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 118. India Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 119. India Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 120. Australia Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 121. Australia Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 122. Germany Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 123. Germany Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 124. France Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 125. France Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 126. UK Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 127. UK Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 128. Italy Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 129. Italy Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 130. Russia Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 131. Russia Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 132. Spain Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 133. Spain Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 134. Egypt Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 135. Egypt Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 136. South Africa Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 137. South Africa Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 138. Israel Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 139. Israel Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 140. Turkey Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 141. Turkey Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 142. GCC Countries Oncology Biosimilars Consumption 2021-2025 (K Units)
Figure 143. GCC Countries Oncology Biosimilars Value 2021-2025 ($ Millions)
Figure 144. Celltrion Oncology Biosimilars Market Share (2018-2020)
Figure 145. BIOCAD Oncology Biosimilars Market Share (2018-2020)
Figure 146. Biocon Oncology Biosimilars Market Share (2018-2020)
Figure 147. STADA Arzneimittel AG Oncology Biosimilars Market Share (2018-2020)
Figure 148. Intas Pharmaceuticals Oncology Biosimilars Market Share (2018-2020)
Figure 149. Dr. Reddy's Laboratories Oncology Biosimilars Market Share (2018-2020)
Figure 150. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Market Share (2018-2020)
Figure 151. Pfizer Oncology Biosimilars Market Share (2018-2020)
Figure 152. Apotex Oncology Biosimilars Market Share (2018-2020)
Figure 153. Sandoz International Oncology Biosimilars Market Share (2018-2020)
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets